Please rotate your device

YOUR ACTION PLAN FOR THE
ETHMOID SINUS

Factors to consider when selecting your PROPEL tool of choice

  • PROPEL is a cylindrical-shaped implant, 23 mm in nominal length, and indicated for the ethmoid sinuses1
  • PROPEL Mini is also a cylindrical-shaped implant, but 16 mm in nominal length, and indicated for ethmoid sinus and the frontal sinus recess2
  • PROPEL Mini is available for use with a straight delivery system designed for easy implant delivery into the ethmoid sinus

Introducing: The PROPEL Mini Straight Delivery System (SDS) designed for optimized delivery of PROPEL Mini to the ethmoid sinus (sold separately)

Patients appropriate for PROPEL and PROPEL Mini

  • ≥18 years of age1,2

  • With and without polyps3

  • Undergoing primary or revision ethmoid sinus surgery3

PROPEL MINI is a smaller version of PROPEL, and was approved for use in the ethmoid sinus based on the demonstrated efficacy and safety profile of PROPEL2

PROPEL is the only sinus surgery implant clinically proven and supported by Level 1-A EVIDENCE to significantly improve outcomes of ethmoid sinus surgery3

Efficacy ENDPOINT: PROPEL delivers significant reduction in the need for postoperative interventions3

35
Relative
reduction

PROPEL reduced the need for postoperative interventions vs a non-drug implant, at 30 days following ethmoid sinus surgery (32.8% vs 50.8%; P=0.0008; N=143)*†

In a subgroup analysis, both patients with and without polyps experienced significant relative reductions in the need for postoperative interventions vs a non-drug implant

36
Reduction

With polyps (n=91):
36% reduction
(32.5% vs 50.6%; P=0.0071)

35
Reduction

Without polyps (n=52):
35% reduction
(33.3% vs 51.1%; P=0.0455)

*Postoperative interventions was a composite endpoint that included surgical intervention required to separate an adhesion and/or oral steroid intervention to resolve recurrent ethmoid sinus inflammation, edema, and/or polyp recurrence.

Judged by an independent panel.

efficacy ENDPOINTS: PROPEL delivers added benefits to patients undergoing ethmoid sinus surgery3

The benefits of PROPEL in reducing the need for postoperative interventions vs a non-drug implant following ethmoid sinus surgery were supported by reductions in oral steroids, polyposis, adhesions/scarring, and middle turbinate lateralization3

RELATIVE REDUCTIONS AT DAY 303

MT, middle turbinate.

*Judged by independent panel.

Judged by on-site clinical investigators.

Study Design: Data presented here represent a meta-analysis of two prospective, randomized, double-blinded multicenter studies (Pilot and ADVANCE II) that enrolled a total of 143 patients. The studies evaluated outcomes of ethmoid sinus surgery with PROPEL placement compared to a non-drug implant, both with standard postoperative care. The studies used an intra-patient control design to evaluate clinical outcomes.3

Patients undergoing ESS with PROPEL resulted in significant symptom reduction through 6 months

Surgery + PROPEL significantly reduced patient-reported symptoms through 6 months following sinus surgery, as reported by SNOT-22 and RSDI1*

RSDI, Rhinosinusitis Disability Index; SNOT-22, Sino-Nasal Outcome Test-22.

*SNOT-22 evaluates rhinologic, extra-nasal rhinologic, ear/facial, psychological dysfunction and sleep dysfunction symptoms.4 RSDI evaluates physical, functional, and emotional symptoms.5

Learn more about the benefits of PROPEL after ethmoid sinus surgery

For significant improvements to patient outcomes following sinus surgery, add PROPEL to your action plan for the ethmoid sinus

PATIENT A*

Non-Drug Implant

Day 0

Day 30

PROPEL

Day 0

Day 30

*Representative outcomes in bilateral sinuses of a single patient from a PROPEL clinical study. Individual results may vary.

Optimal treatment following ethmoid sinus surgery with a full arsenal of options including PROPEL and PROPEL Mini can help improve patient outcomes

PROPEL has a PROVEN safety profile1

The safety profile of PROPEL was established across three prospective clinical trials including 205 patients.1 The most common adverse reactions observed (≥2% of subjects and that occurred more frequently in the treatment group compared to control) in clinical studies were sinusitis, headache, epistaxis and bronchitis.

GET PROPEL

Stay Informed

This site is intended for healthcare professionals in the United States

Stay Informed

References

  1. PROPEL [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013.
  2. PROPEL Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
  3. Han JK, Marple BF, Smith TL, et al. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. Int Forum Allergy Rhinol. 2012;2(4):271-279.
  4. Deconde AS, Bodner TE, Mace JC, Smith TL. Response shift in quality of life after endoscopic sinus surgery for chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg. 2014;140(8):712-719.
  5. Benninger MS, Senior BA. The development of the Rhinosinusitis Disability Index. Arch Otolaryngol Head Neck Surg. 1997;123(11):1175-1179.